First Time Loading...

Adaptimmune Therapeutics PLC
NASDAQ:ADAP

Watchlist Manager
Adaptimmune Therapeutics PLC Logo
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
Watchlist
Price: 1.075 USD 1.42% Market Closed
Updated: Apr 29, 2024

Adaptimmune Therapeutics PLC
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Adaptimmune Therapeutics PLC
Revenue Peer Comparison

Comparables:
CNTA
AUTL
BCYC
IMCR
GNS

Competitive Revenue Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
Revenue
$60.3m
CAGR 3-Years
148%
CAGR 5-Years
0%
CAGR 10-Years
N/A
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Revenue
$6.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Autolus Therapeutics PLC
NASDAQ:AUTL
Revenue
$1.7m
CAGR 3-Years
0%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bicycle Therapeutics PLC
NASDAQ:BCYC
Revenue
$27m
CAGR 3-Years
37%
CAGR 5-Years
30%
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
Revenue
£249.4m
CAGR 3-Years
102%
CAGR 5-Years
60%
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Revenue
£673.1m
CAGR 3-Years
6%
CAGR 5-Years
7%
CAGR 10-Years
6%

Adaptimmune Therapeutics PLC
Revenue Breakdown

Breakdown by Geography
Adaptimmune Therapeutics PLC

Not Available

Breakdown by Segments
Adaptimmune Therapeutics PLC

Total Revenue: 60.3m USD
100%
Refers To Development Revenue: 60.3m USD
100%

See Also

What is Adaptimmune Therapeutics PLC's Revenue?
Revenue
60.3m USD

Based on the financial report for Dec 31, 2023, Adaptimmune Therapeutics PLC's Revenue amounts to 60.3m USD.

What is Adaptimmune Therapeutics PLC's Revenue growth rate?
Revenue CAGR 5Y
0%

Over the last year, the Revenue growth was 122%. The average annual Revenue growth rates for Adaptimmune Therapeutics PLC have been 148% over the past three years .